Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Noom will start offering smaller doses of compounded Wegovy (NVO), the blockbuster weight-loss drug, as the digital health ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

On a weekday morning in Dublin, a group of patients walked into a weight-loss clinic hoping to shed pounds. What they didn’t expect was to also lose their taste for alcohol. A new study has found that ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

(Note: The Hers platform offers access to Wegovy, if prescribed, for people 18 and older, at 50 percent off the retail price.) It’s a powerful tool for weight loss, but it’s not a magic ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...